These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 9146777

  • 1. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
    [Abstract] [Full Text] [Related]

  • 2. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS, Rowley JL.
    Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group.
    Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
    [Abstract] [Full Text] [Related]

  • 4. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
    Jansen JB, Van Oene JC.
    Aliment Pharmacol Ther; 1999 Dec; 13(12):1611-20. PubMed ID: 10594396
    [Abstract] [Full Text] [Related]

  • 5. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
    Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):529-39. PubMed ID: 8853756
    [Abstract] [Full Text] [Related]

  • 6. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 7. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S, Italian Lansoprazole Study Group.
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1093-9. PubMed ID: 9663835
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
    Sontag SJ, Schnell TG, Chejfec G, Kurucar C, Karpf J, Levine G.
    Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
    [Abstract] [Full Text] [Related]

  • 12. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
    Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK, Brocklebank D.
    Aliment Pharmacol Ther; 1995 Apr; 9(2):145-51. PubMed ID: 7605854
    [Abstract] [Full Text] [Related]

  • 13. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
    Hatlebakk JG, Berstad A, Carling L, Svedberg LE, Unge P, Ekström P, Halvorsen L, Stallemo A, Hovdenak N, Trondstad R.
    Scand J Gastroenterol; 1993 Mar; 28(3):224-8. PubMed ID: 8446846
    [Abstract] [Full Text] [Related]

  • 14. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA.
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [Abstract] [Full Text] [Related]

  • 15. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjánsdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A.
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.
    Sontag SJ, Robinson M, Roufail W, Hirschowitz BI, Sabesin SM, Wu WC, Behar J, Peterson WL, Kranz KR, Tarnawski A, Dayal Y, Berman R, Simon TJ.
    Aliment Pharmacol Ther; 1997 Apr; 11(2):373-80. PubMed ID: 9146778
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.